AU2003206862A8 - Hepatitis b vaccines - Google Patents
Hepatitis b vaccinesInfo
- Publication number
- AU2003206862A8 AU2003206862A8 AU2003206862A AU2003206862A AU2003206862A8 AU 2003206862 A8 AU2003206862 A8 AU 2003206862A8 AU 2003206862 A AU2003206862 A AU 2003206862A AU 2003206862 A AU2003206862 A AU 2003206862A AU 2003206862 A8 AU2003206862 A8 AU 2003206862A8
- Authority
- AU
- Australia
- Prior art keywords
- vaccines
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0202901.5A GB0202901D0 (en) | 2002-02-07 | 2002-02-07 | Novel vaccine |
GB0202901.5 | 2002-02-07 | ||
PCT/EP2003/001214 WO2003066094A2 (en) | 2002-02-07 | 2003-02-05 | Hepatitis b vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2003206862A1 AU2003206862A1 (en) | 2003-09-02 |
AU2003206862A8 true AU2003206862A8 (en) | 2003-09-02 |
Family
ID=9930627
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003206862A Abandoned AU2003206862A1 (en) | 2002-02-07 | 2003-02-05 | Hepatitis b vaccines |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003206862A1 (en) |
GB (1) | GB0202901D0 (en) |
WO (1) | WO2003066094A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070292386A9 (en) * | 2004-12-02 | 2007-12-20 | Campbell Robert L | Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents |
GB0505518D0 (en) | 2005-03-17 | 2005-04-27 | Chiron Srl | Combination vaccines with whole cell pertussis antigen |
EP1871411A4 (en) | 2005-04-18 | 2010-07-21 | Novartis Vaccines & Diagnostic | Expressing hepatitis b virus surface antigen for vaccine preparation |
US8007807B2 (en) | 2005-09-01 | 2011-08-30 | Novartis Vaccines And Diagnostics Gmbh | Multiple vaccination including serogroup C meningococcus |
EP1862176A1 (en) * | 2006-05-31 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Method for producing a vaccine composition |
EP1862177A1 (en) * | 2006-06-01 | 2007-12-05 | Rhein Biotech Gesellschaft für neue biotechnologische Prozesse und Produkte mbH | Method for producing a vaccine composition |
CA2793510A1 (en) | 2010-03-18 | 2012-02-16 | Novartis Ag | Adjuvanted vaccines for serogroup b meningococcus |
TR201811280T4 (en) | 2011-03-02 | 2018-08-27 | Glaxosmithkline Biologicals Sa | Mixed vaccines with low antigen and / or adjuvant doses. |
DE102011118371B4 (en) | 2011-11-11 | 2014-02-13 | Novartis Ag | Composition suitable for human vaccination, comprising a diphtheria toxoid, and process for its preparation |
EP2592137A1 (en) | 2011-11-11 | 2013-05-15 | Novartis AG | Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use |
GB2495341B (en) | 2011-11-11 | 2013-09-18 | Novartis Ag | Fermentation methods and their products |
DE102011122891B4 (en) | 2011-11-11 | 2014-12-24 | Novartis Ag | Fermentation medium, which is free of animal components, for the preparation of diphtheria toxoids for use in the vaccination of humans |
WO2013132043A1 (en) | 2012-03-08 | 2013-09-12 | Novartis Ag | Combination vaccines with tlr4 agonists |
JP6324961B2 (en) | 2012-09-06 | 2018-05-16 | ノバルティス アーゲー | Combination vaccine of serogroup B meningococcus and D / T / P |
EP2906239A1 (en) | 2012-10-12 | 2015-08-19 | GlaxoSmithKline Biologicals SA | Non-cross-linked acellular pertussis antigens for use in combination vaccines |
JP2016502994A (en) | 2012-12-18 | 2016-02-01 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | Conjugates to protect against diphtheria and / or tetanus |
EP3184639B1 (en) * | 2014-08-21 | 2019-06-12 | Chung-Ang University Industry-Academy Cooperation Foundation | Rdna nts based gene multiple insertion cassette set and gras-grade recombinant yeast strain |
CN106222129A (en) * | 2016-07-29 | 2016-12-14 | 广东东阳光药业有限公司 | A kind of cell culture medium improving antibody purity and cultural method |
EP3634996A4 (en) * | 2017-06-06 | 2021-03-03 | InDevR, Inc. | Simultaneous in vitro analysis of vaccine potency and toxin concentration |
EP3799884A1 (en) | 2019-10-01 | 2021-04-07 | GlaxoSmithKline Biologicals S.A. | Immunogenic compositions |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2278684C (en) * | 1997-02-06 | 2007-04-10 | Merck & Co., Inc. | Thimerosal-free preservatives for vaccines |
UA79735C2 (en) * | 2000-08-10 | 2007-07-25 | Глаксосмітклайн Байолоджікалз С.А. | Purification of hbv antigens for use in vaccines |
-
2002
- 2002-02-07 GB GBGB0202901.5A patent/GB0202901D0/en not_active Ceased
-
2003
- 2003-02-05 AU AU2003206862A patent/AU2003206862A1/en not_active Abandoned
- 2003-02-05 WO PCT/EP2003/001214 patent/WO2003066094A2/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
GB0202901D0 (en) | 2002-03-27 |
WO2003066094A2 (en) | 2003-08-14 |
WO2003066094A3 (en) | 2003-12-24 |
AU2003206862A1 (en) | 2003-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003206862A8 (en) | Hepatitis b vaccines | |
PL376967A1 (en) | Vaccine against hcv | |
GB0225788D0 (en) | Vaccine | |
AU2003285320A8 (en) | Vaccine | |
GB0212046D0 (en) | Vaccines | |
GB0228715D0 (en) | Vaccine | |
GB0323840D0 (en) | Vaccines | |
GB0328753D0 (en) | Hepatitis B vaccines | |
GB0209878D0 (en) | Vaccine | |
PL376534A1 (en) | Vaccine | |
GB0321614D0 (en) | Vaccines | |
GB0212036D0 (en) | Vaccines | |
GB0304634D0 (en) | Vaccines | |
GB0206595D0 (en) | Vaccine | |
GB0229200D0 (en) | Hepatitis B vaccines | |
IL156434A0 (en) | Vaccine | |
GB0223355D0 (en) | Vaccine | |
GB0226179D0 (en) | Vaccine | |
GB0330007D0 (en) | Vaccines | |
GB0217721D0 (en) | Vaccines | |
GB0206462D0 (en) | Vaccines | |
GB0200829D0 (en) | Vaccines | |
GB0220212D0 (en) | Vaccine | |
GB0219626D0 (en) | Vaccine | |
GB0206054D0 (en) | Vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |